Transaction · 0001193125-26-382456

Vieira Roberto Wandenkolk

Vieira Roberto Wandenkolk, PRES, reported a transaction classified as exercise at CORCEPT THERAPEUTICS INC involving 58333.000000 shares for an estimated $1261742.79. Reported holdings after the transaction were 62575.000000 shares. The stored filing text includes a detected 10b5-1 reference.

exerciseSEC transaction code MPRES
CORTCORCEPT THERAPEUTICS INC
Trade date
Sep 02, 2026
Filing date
Sep 04, 2026
View on SEC Insider profile
Estimated value$1.26MShares × reported price
Shares traded58.3k$21.63 per share
Holdings after62.5kDirect
% of reported position tradedUnavailableThis security and ownership context
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

CORT price since this filing

Daily closing prices, with the filing date and available return windows
CORT · Daily closing priceLoading daily prices…
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +1.1%1w ago +7.3%1d ago +1.6%
Returns since7d +1.0%30d +4.1%90d180d1y

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
exercise
Code M
Identifier
0001193125-26-382456
Common Stock
Transaction date
Sep 02, 2026
Filed Sep 04, 2026, 01:02 AM · 2d delay
Shares
58,333 sh
$21.63 per share
Estimated value
$1.26M
Computed from shares × price
Holdings after
62,575 sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Direct Ownership Large Holdings Increase 10b5-1 Detected
Filing-only score

0 points

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

How this score is calculated
  • direct_ownership+6 points

    direct_or_indirect_ownership = D

    Direct ownership reports the insider's personal stake.
  • timely_filing+4 points

    reporting_delay_days = 2

    Filing reported within two business days of the transaction.
  • tenb5_1_detected-10 points

    is_10b5_1 = true

    Stored filing content includes detected 10b5-1 language.
Read the scoring methodology

Signed filing-only points, not a probability or expected return. Version v1.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

President, Oncology

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 I…

  2. F2

    In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

  3. F3

    Includes 199 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 2, 2025, 179 shares underlying unvested restricted stock awards granted to th…

  4. F4

    Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-y…

  5. F5

    These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of restricted stock units.

  6. F6

    The closing price on September 1, 2026 was used to calculate the withholding obligation.

  7. F7

    Includes 179 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 396 shares underlying unvested restricted stock awards granted to the…

  8. F8

    This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on June 17, 2026, prior to the reporting person being appointed an officer of the Issuer, which was in effect at the…

  9. F9

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $108.97 to $109.83 per share. Information on the exact number of shares sold at each…

  10. F10

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $110.06 to $111.03 per share. Information on the exact number of shares sold at each…

  11. F11

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $111.06 to $111.945 per share. Information on the exact number of shares sold at each…

  12. F12

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $112.08 to $113.03 per share. Information on the exact number of shares sold at each…

  13. F13

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $113.11 to $114.09 per share. Information on the exact number of shares sold at each…

  14. F14

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $114.24 to $115.195 per share. Information on the exact number of shares sold at each…

  15. F15

    Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $115.255 to $115.57 per share. Information on the exact number of shares sold at each…

  16. F16

    Shares subject to the stock option vested and became exercisable with respect to 25% of the shares underlying the option on January 29, 2025 with the remaining shares vesting and becoming exercisable…

Original filing · 0001193125-26-382456
Related transactions

0 other transactions

Same SEC filing
Recent company activity

0 recent txs

CORT